Zoetis
Zoetis Inc., headquartered in the United States, is a leading global animal health company dedicated to supporting the health and well-being of livestock and companion animals. Founded in 1952, Zoetis has established itself as a pioneer in the veterinary pharmaceutical industry, with a diverse portfolio that includes vaccines, diagnostics, and therapeutics. With a strong presence in North America, Europe, and Asia, Zoetis is renowned for its innovative products that enhance animal health and productivity. The company’s commitment to research and development has led to significant milestones, including the introduction of groundbreaking treatments that address various health challenges in animals. Recognised for its market leadership, Zoetis continues to set industry standards, making it a trusted partner for veterinarians and animal producers worldwide.
DitchCarbon Score
How does Zoetis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zoetis's score of 38 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zoetis's reported carbon emissions
In 2023, Zoetis reported total carbon emissions of approximately 232,804,000 kg CO2e, comprising 111,637,000 kg CO2e from Scope 1, 121,167,000 kg CO2e from Scope 2, and additional emissions from Scope 3, including 21,399,000 kg CO2e from business travel and 14,935,000 kg CO2e from employee commuting. Over the years, Zoetis has made significant strides in reducing its carbon footprint. From 2017 to 2023, the company has aimed to become carbon neutral in its operations by 2030, targeting all scopes of emissions. This commitment reflects a long-term strategy to mitigate climate impact and aligns with industry standards for sustainability. In 2022, the total emissions were about 303,186,000 kg CO2e, indicating a reduction in emissions over the following year. The company has consistently reported its emissions across Scopes 1, 2, and 3, demonstrating transparency in its sustainability efforts. Zoetis's ongoing initiatives and clear reduction targets position it as a responsible leader in the veterinary pharmaceutical industry, committed to addressing climate change and reducing its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 73,391,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 193,434,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zoetis is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
